Courant.com


  Archives
Document
Advanced Saved Page Prints Help
Buy Complete Document: AbstractAbstract Full Text Full Text Buy Page Print Page Print
ADVANCE REPORTED IN BREAST CANCER TREATMENT CONNECTICUT WOMEN TOOK PART IN TAMOXIFEN STUDY
[STATEWIDE Edition 2]
Hartford Courant - Hartford, Conn.
Author: Staff And Wire Reports Courant Staff Writers Stacy Wong, Paul Johnson and Marie K. Shanahan contributed to this story.
Date: Apr 7, 1998
Start Page: A.1
Section: MAIN (A)
Text Word Count: 1584
Abstract (Document Summary)

Correction was published April 8, 1998 on Page A2. * A story on Page 1 Tuesday inaccurately reported the relationship between the age menstruation begins and the risk of developing breast cancer. The younger a girl begins menstruation, the greater the risk of breast cancer. A graphic that accompanied the story was correct. The same graphic failed to explain the relationship between biopsies and the risk for breast cancer. Biopsies are ordered as a result of mammograms and other tests that indicate breast cancer may be present; biopsies do not increase the risk of developing cancer.

The phone calls were prompted by the announcement that tamoxifen can reduce breast cancer cases by 45 percent in women at high risk. The calls were made despite the warning that tamoxifen is not for everyone, and that it has possible side effects ranging from increased chances of uterine cancer to life-threatening blood clots and threats to fertility.

Tamoxifen is one of a class of drugs called selective estrogen response modifiers. They function like double agents, mimicking estrogen in one part of the body and acting against it in another. Tamoxifen acts like estrogen by lowering blood cholesterol and slowing bone loss. It neutralizes the effects of estrogen in the breast.

Buy Complete Document: AbstractAbstract Full Text Full Text Buy Page Print Page Print

Most Viewed Articles  (Updated Daily)